A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma
Immune checkpoint inhibitors (ICIs) are used to treat a variety of tumors. Despite their broad beneficial effects, these inhibitors can cause immune-related adverse events (irAEs) and even death. Hemophagocytic lymphohistiocytosis (HLH) and meningitis, although infrequent, can be aggressive and life...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2024-04, Vol.16 (4), p.e58253 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | e58253 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 16 |
| creator | Ota, Hiroaki Munechika, Miyuki Tobino, Kazunori Uchida, Kazuki Muarakami, Yosuke |
| description | Immune checkpoint inhibitors (ICIs) are used to treat a variety of tumors. Despite their broad beneficial effects, these inhibitors can cause immune-related adverse events (irAEs) and even death. Hemophagocytic lymphohistiocytosis (HLH) and meningitis, although infrequent, can be aggressive and life-threatening due to excessive immune activation. Herein, we report a case of an 80-year-old man who developed HLH after receiving atezolizumab monotherapy as a second-line treatment for lung adenocarcinoma. He was treated for HLH with oral prednisolone (PSL), but further ataxia and dysuria developed, and a lumbar puncture diagnosed meningitis. Both HLH and meningitis improved with continued oral PSL treatment. This is the first case of atezolizumab-induced HLH with meningitis and highlights the importance of early diagnosis and treatment for rare irAE. |
| doi_str_mv | 10.7759/cureus.58253 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11091938</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3062800418</sourcerecordid><originalsourceid>FETCH-LOGICAL-c267t-80772a559299d2c575d44c6f040f149f1be4bf9b8bc01b80a73150d6a8030e83</originalsourceid><addsrcrecordid>eNpVkd1LwzAUxYMoOnRvPkvAVzdv2qZJn2TMT5gIsveQpumWsSY1ScXtr3dzOubT_Tqce-CH0CWBIWO0uFWd110YUp7Q9Aj1EpLzASc8Oz7oz1A_hAUAEGAJMDhFZylnGeVAeuhrhMcyaPyuW-cjdjV-1o1r53Lm1CoahSerpp27uQnRbDcumIClrfCrtsbOTNyM953G0eFR1Gu3NOuukSWeei1jo23EtfN40tkZHlXaOiW9MtY18gKd1HIZdP-3nqPp48N0_DyYvD29jEeTgUpyFgccGEskpUVSFFWiKKNVlqm8hgxqkhU1KXVW1kXJSwWk5CBZSihUueSQgubpObrb2bZd2ehKbRJ5uRStN430K-GkEf8v1szFzH0KQqAgRbp1uP518O6j0yGKheu83WQWKeQJB8jIVnWzUynvQvC63r8gILaoxA6V-EG1kV8dxtqL_8Ck387jkp8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3062800418</pqid></control><display><type>article</type><title>A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma</title><source>PubMed Central Open Access</source><source>PubMed</source><creator>Ota, Hiroaki ; Munechika, Miyuki ; Tobino, Kazunori ; Uchida, Kazuki ; Muarakami, Yosuke</creator><creatorcontrib>Ota, Hiroaki ; Munechika, Miyuki ; Tobino, Kazunori ; Uchida, Kazuki ; Muarakami, Yosuke</creatorcontrib><description>Immune checkpoint inhibitors (ICIs) are used to treat a variety of tumors. Despite their broad beneficial effects, these inhibitors can cause immune-related adverse events (irAEs) and even death. Hemophagocytic lymphohistiocytosis (HLH) and meningitis, although infrequent, can be aggressive and life-threatening due to excessive immune activation. Herein, we report a case of an 80-year-old man who developed HLH after receiving atezolizumab monotherapy as a second-line treatment for lung adenocarcinoma. He was treated for HLH with oral prednisolone (PSL), but further ataxia and dysuria developed, and a lumbar puncture diagnosed meningitis. Both HLH and meningitis improved with continued oral PSL treatment. This is the first case of atezolizumab-induced HLH with meningitis and highlights the importance of early diagnosis and treatment for rare irAE.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.58253</identifier><identifier>PMID: 38745801</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Blood ; Blood platelets ; Bone marrow ; Case reports ; Chemotherapy ; Chronic obstructive pulmonary disease ; Encephalitis ; Immunotherapy ; Leukocytes ; Lung cancer ; Melanoma ; Meningitis ; Monoclonal antibodies ; Oncology ; Patients ; Pulmonology ; Skin cancer ; Steroids ; Targeted cancer therapy</subject><ispartof>Curēus (Palo Alto, CA), 2024-04, Vol.16 (4), p.e58253</ispartof><rights>Copyright © 2024, Ota et al.</rights><rights>Copyright © 2024, Ota et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2024, Ota et al. 2024 Ota et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c267t-80772a559299d2c575d44c6f040f149f1be4bf9b8bc01b80a73150d6a8030e83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091938/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091938/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38745801$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ota, Hiroaki</creatorcontrib><creatorcontrib>Munechika, Miyuki</creatorcontrib><creatorcontrib>Tobino, Kazunori</creatorcontrib><creatorcontrib>Uchida, Kazuki</creatorcontrib><creatorcontrib>Muarakami, Yosuke</creatorcontrib><title>A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Immune checkpoint inhibitors (ICIs) are used to treat a variety of tumors. Despite their broad beneficial effects, these inhibitors can cause immune-related adverse events (irAEs) and even death. Hemophagocytic lymphohistiocytosis (HLH) and meningitis, although infrequent, can be aggressive and life-threatening due to excessive immune activation. Herein, we report a case of an 80-year-old man who developed HLH after receiving atezolizumab monotherapy as a second-line treatment for lung adenocarcinoma. He was treated for HLH with oral prednisolone (PSL), but further ataxia and dysuria developed, and a lumbar puncture diagnosed meningitis. Both HLH and meningitis improved with continued oral PSL treatment. This is the first case of atezolizumab-induced HLH with meningitis and highlights the importance of early diagnosis and treatment for rare irAE.</description><subject>Blood</subject><subject>Blood platelets</subject><subject>Bone marrow</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Encephalitis</subject><subject>Immunotherapy</subject><subject>Leukocytes</subject><subject>Lung cancer</subject><subject>Melanoma</subject><subject>Meningitis</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pulmonology</subject><subject>Skin cancer</subject><subject>Steroids</subject><subject>Targeted cancer therapy</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpVkd1LwzAUxYMoOnRvPkvAVzdv2qZJn2TMT5gIsveQpumWsSY1ScXtr3dzOubT_Tqce-CH0CWBIWO0uFWd110YUp7Q9Aj1EpLzASc8Oz7oz1A_hAUAEGAJMDhFZylnGeVAeuhrhMcyaPyuW-cjdjV-1o1r53Lm1CoahSerpp27uQnRbDcumIClrfCrtsbOTNyM953G0eFR1Gu3NOuukSWeei1jo23EtfN40tkZHlXaOiW9MtY18gKd1HIZdP-3nqPp48N0_DyYvD29jEeTgUpyFgccGEskpUVSFFWiKKNVlqm8hgxqkhU1KXVW1kXJSwWk5CBZSihUueSQgubpObrb2bZd2ehKbRJ5uRStN430K-GkEf8v1szFzH0KQqAgRbp1uP518O6j0yGKheu83WQWKeQJB8jIVnWzUynvQvC63r8gILaoxA6V-EG1kV8dxtqL_8Ck387jkp8</recordid><startdate>20240414</startdate><enddate>20240414</enddate><creator>Ota, Hiroaki</creator><creator>Munechika, Miyuki</creator><creator>Tobino, Kazunori</creator><creator>Uchida, Kazuki</creator><creator>Muarakami, Yosuke</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20240414</creationdate><title>A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma</title><author>Ota, Hiroaki ; Munechika, Miyuki ; Tobino, Kazunori ; Uchida, Kazuki ; Muarakami, Yosuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c267t-80772a559299d2c575d44c6f040f149f1be4bf9b8bc01b80a73150d6a8030e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Blood</topic><topic>Blood platelets</topic><topic>Bone marrow</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Encephalitis</topic><topic>Immunotherapy</topic><topic>Leukocytes</topic><topic>Lung cancer</topic><topic>Melanoma</topic><topic>Meningitis</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pulmonology</topic><topic>Skin cancer</topic><topic>Steroids</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ota, Hiroaki</creatorcontrib><creatorcontrib>Munechika, Miyuki</creatorcontrib><creatorcontrib>Tobino, Kazunori</creatorcontrib><creatorcontrib>Uchida, Kazuki</creatorcontrib><creatorcontrib>Muarakami, Yosuke</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ota, Hiroaki</au><au>Munechika, Miyuki</au><au>Tobino, Kazunori</au><au>Uchida, Kazuki</au><au>Muarakami, Yosuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2024-04-14</date><risdate>2024</risdate><volume>16</volume><issue>4</issue><spage>e58253</spage><pages>e58253-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Immune checkpoint inhibitors (ICIs) are used to treat a variety of tumors. Despite their broad beneficial effects, these inhibitors can cause immune-related adverse events (irAEs) and even death. Hemophagocytic lymphohistiocytosis (HLH) and meningitis, although infrequent, can be aggressive and life-threatening due to excessive immune activation. Herein, we report a case of an 80-year-old man who developed HLH after receiving atezolizumab monotherapy as a second-line treatment for lung adenocarcinoma. He was treated for HLH with oral prednisolone (PSL), but further ataxia and dysuria developed, and a lumbar puncture diagnosed meningitis. Both HLH and meningitis improved with continued oral PSL treatment. This is the first case of atezolizumab-induced HLH with meningitis and highlights the importance of early diagnosis and treatment for rare irAE.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>38745801</pmid><doi>10.7759/cureus.58253</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2024-04, Vol.16 (4), p.e58253 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11091938 |
| source | PubMed Central Open Access; PubMed |
| subjects | Blood Blood platelets Bone marrow Case reports Chemotherapy Chronic obstructive pulmonary disease Encephalitis Immunotherapy Leukocytes Lung cancer Melanoma Meningitis Monoclonal antibodies Oncology Patients Pulmonology Skin cancer Steroids Targeted cancer therapy |
| title | A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A30%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Case%20Report%20of%20Hemophagocytic%20Lymphohistiocytosis%20and%20Meningitis%20Due%20to%20Atezolizumab%20Treatment%20for%20Lung%20Adenocarcinoma&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Ota,%20Hiroaki&rft.date=2024-04-14&rft.volume=16&rft.issue=4&rft.spage=e58253&rft.pages=e58253-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.58253&rft_dat=%3Cproquest_pubme%3E3062800418%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3062800418&rft_id=info:pmid/38745801&rfr_iscdi=true |